Related references
Note: Only part of the references are listed.Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease
Brindusa Truta et al.
INFLAMMATORY BOWEL DISEASES (2020)
Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease
David J. Gibson et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Anti-TNF treatment during pregnancy and birth outcomes: Apopulation-based study from Denmark, Finland, and Sweden
Gabriella Broms et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De-Escalation in Adults With Inflammatory Bowel Diseases
Antoine Petitcollin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Optimising infliximab induction dosing for patients with ulcerative colitis
Erwin Dreesen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group
Uma Mahadevan et al.
GASTROENTEROLOGY (2019)
Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION)
Maxime Luu et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration
David Ternant et al.
CLINICAL PHARMACOKINETICS (2018)
American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
Niels Vande Casteele et al.
GASTROENTEROLOGY (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and implications for vaccination in Pregnancy
Christopher R. Wilcox et al.
FRONTIERS IN IMMUNOLOGY (2017)
The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease
C. H. Seow et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety
A. de Lima et al.
GUT (2016)
Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection
Mette Julsgaard et al.
GASTROENTEROLOGY (2016)
Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies
Casper Steenholdt et al.
INFLAMMATORY BOWEL DISEASES (2016)
Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis
Zaid Shihab et al.
JOURNAL OF CROHNS & COLITIS (2016)
A comprehensive review of the neonatal Fc receptor and its application in drug delivery
Joao Pedro Martins et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease
David Ternant et al.
CLINICAL PHARMACOKINETICS (2015)
The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease
C. J. van der Woude et al.
JOURNAL OF CROHNS & COLITIS (2015)
Placental Transfer of Anti-Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
Uma Mahadevan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development-Part 2: Introduction to Pharmacokinetic Modeling Methods
Dr Mould et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31
Casper Steenholdt et al.
JOURNAL OF CROHNS & COLITIS (2012)
High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy
Z. Zelinkova et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models
Xu Steven Xu et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2011)
Placental Transport of Immunoglobulins: A Clinical Review for Gastroenterologists Who Prescribe Therapeutic Monoclonal Antibodies to Women During Conception and Pregnancy
Sunanda V. Kane et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Share Paper
